Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13863427 | 0.97 | LMNA (0.45) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL751071 | 0.94 | LMNA (0.43) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL15282771 | 0.94 | LMNA (0.43) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL6049114 | 0.94 | LMNA (0.43) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL15282759 | 0.88 | APP (0.42) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL6049116 | 0.86 | TDP1 (0.53) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL11188669 | 0.84 | PTGS1 (0.36) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL10060664 | 0.84 | TDP1 (0.37) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL15297848 | 0.82 | TSHR (0.37) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL32679299 | 0.81 | PTGS1 (0.43) | LMNAPTGS1PDE4ASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249826-B1 | COMPOSITIONS AND METHODS OF USE OF COMPOUNDS TO INCREASE CANCER PATIENT SURVIVAL TIME | BIONUMERIK PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | claimed |
| EP-2249825-B1 | TREATMENT METHODS AND COMPOSITIONS FOR LUNG CANCER, ADENOCARCINOMA, AND OTHER MEDICAL CONDITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2015-10-07 | — | — | EP | claimed |
| EP-1991237-B1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2252246-B1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2014-06-18 | — | — | EP | claimed |
| EP-1033981-B1 | FORMULATIONS AND METHODS FOR REDUCING TOXICITY OF ANTINEOPLASTIC AGENTS | BIONUMERIK PHARMACEUTICALS INC (US) | 2004-03-24 | — | — | EP | claimed |
| US-20230210794-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | LANTERN PHARMA INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20180369173-A9 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20160287540-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287539-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2249826-B1 | COMPOSITIONS AND METHODS OF USE OF COMPOUNDS TO INCREASE CANCER PATIENT SURVIVAL TIME | BIONUMERIK PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9320760-B2 | Compositions and methods of use of compounds to increase cancer patient survival time | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2249825-B1 | TREATMENT METHODS AND COMPOSITIONS FOR LUNG CANCER, ADENOCARCINOMA, AND OTHER MEDICAL CONDITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-6046234-A | REDUCING THE TOXICITY OF AN ALKYLATING AGENT ADMINISTERED TO A PATIENT AS THERAPY FOR CANCER, COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ALKYLATING AGENT AND A TOXICITY REDUCING SULFIDE OR DISULFIDE COMPOUND | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-6043249-A | THE COMPOUNDS HAVE EITHER A SULFHYDRYL MOIETY OR ARE REDUCIBLE DISULFIDES; ANTIFOLATES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-6040294-A | THE COMPOUNDS HAVE EITHER A SULFHYDRYL MOIETY OR ARE REDUCIBLE DISULFIDES; REDUCING THE SIDE EFFECT OF CANCER DRUG | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6040312-A | THE COMPOUNDS HAVE EITHER A SULFHYDRYL MOIETY OR ARE REDUCIBLE DISULFIDES; REDUCING THE SIDE EFFECT OF CANCER DRUG, ANTIBIOTICS OR VIRICIDES, A VINCA ALKALOIDS--VINCRISTINE, VINBLASTINE, VINORELBINE, VINDESINE | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6040304-A | THE COMPOUNDS HAVE EITHER A SULFHYDRYL MOIETY OR ARE REDUCIBLE DISULFIDES; REDUCING THE SIDE EFFECT OF CANCER DRUG, ANTIBIOTICS OR VIRICIDES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6025488-A | MIXTURE OF CRYPTOPHYCIN AND CYTOPROTECTIVE SULFUR COMPOUND; DRUG DELIVERY, SIDE EFFECT REDUCTION | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5919816-A | ADMINISTERING DRUG WITH PROTECTIVE AGENT | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1999020264-A1 | FORMULATIONS AND METHODS FOR REDUCING TOXICITY OF ANTINEOPLASTIC AGENTS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287539-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | TXNRD3, TXNRD1, TXN | LMNA 4133/4885PTGS1 377/4885PDE4A 3201/4885 |
| US-20230210794-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | TXNRD3, TXNRD1, TXN | LMNA 4133/4885PTGS1 377/4885PDE4A 3201/4885 |
| US-20160287540-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | TXNRD3, TXNRD1, TXN | LMNA 4133/4885PTGS1 377/4885PDE4A 3201/4885 |
| US-20180369173-A9 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | TXNRD3, TXNRD1, TXN | LMNA 4133/4885PTGS1 377/4885PDE4A 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.